Surefire Medical has raised a $15 million series C round to back a global launch of its liver cancer drug delivery device. The FDA cleared the Surefire Precision earlier this year to conduct minimally invasive chemoembolization and radioembolization procedures.
The blood-brain barrier has proven to be one of the body's most insurmountable barriers and has helped scupper several neurological candidates. A new drug delivery alliance aims to overcome the obstacle by bypassing it all together.
Large molecule biologics aren't easy, convenient or painless for patients to administer since typically they require injections. Portal Instruments hopes to provide an alternative for patients, particularly those with chronic diseases who consistently require these injections. It's developing a computerized, needle-free drug delivery system for injectable biologics.
Massachusetts' EyeGate Pharmaceuticals picked up $10 million in an IPO do-over, raising cash to support its sole clinical candidate.
Eli Lilly will open a new drug delivery and device innovation center in Cambridge, MA. Medical devices aren't a focus for the pharma now--but it noted that more than half of its current pipeline candidates are biologics that require injection. It expects to double its revenues from device-enabled products by 2020 and is looking to have a hand in that arena.
Researchers in the lab of MIT's Robert Langer have created a hydrogel that's designed to be much better than current technologies in getting drugs into patients and straight to where they are targeted.
Montreal-based enGene has lined up $11.5 million in venture financing to put its next-gen approach to an inflammatory bowel disease treatment through its first clinical test.
Medical device giant Medtronic said it reached another milestone in developing an artificial pancreas with the completion of global evaluations of its new insulin delivery system.
Bind Therapeutics believes its lead nanoparticle treatment can make a difference for a subgroup of lung cancer patients, pointing to some positive results from an otherwise mixed mid-stage trial as it prepares for further study.
Billing it as the most important new innovation in the interferon drug class in a decade, Biogen Idec nailed down the FDA's approval of Plegridy, a new multiple sclerosis drug that patients can easily inject themselves with once every two weeks.